Tampere Center for Child, Adolescent and Maternal Health Research, Tays Cancer Centre, Tampere University Hospital, Tampere University, Tampere, Finland.
Pediatric Research Center, University of Helsinki, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Cancer Rep (Hoboken). 2022 Oct;5(10):e1663. doi: 10.1002/cnr2.1663. Epub 2022 Jul 7.
Chronic myeloid leukemia (CML) is a rare disease in children and treated with tyrosine kinase inhibitors (TKI) and with allogeneic hematopoietic stem cell transplantation (HSCT) still in many cases.
We describe an 8-year-old patient with CML treated with two different TKIs before proceeding to allogeneic HSCT. Despite successful engraftment, prompt rejection of the graft was followed by autologous reconstitution. TKI therapy was reintroduced post-rejection in anticipation of relapse but shortly discontinued due to low white blood cell and neutrophil counts. The patient has remained disease-free over 5 years after graft rejection and without further therapy.
This case suggests that even a short antileukemic effect by an allogeneic transplant may succeed in eradicating CML.
慢性髓细胞白血病（CML）在儿童中较为罕见，治疗方法为使用酪氨酸激酶抑制剂（TKI）和异基因造血干细胞移植（HSCT），在许多情况下仍在使用。
我们描述了一位 8 岁的 CML 患者，在进行异基因 HSCT 之前，曾接受过两种不同的 TKI 治疗。尽管成功植入，但随后迅速排斥移植物，随后出现自体重建。在预期复发的情况下，排斥后重新引入 TKI 治疗，但由于白细胞和中性粒细胞计数低，很快停止。排斥后 5 年多来，患者疾病无复发，且未再接受其他治疗。
该病例表明，即使异基因移植有短暂的抗白血病作用，也可能成功根除 CML。
